Eloxx Pharmaceuticals Inc. (ELOX) carries a Roarable Rating of D- (Sell) with 42/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Eloxx Pharmaceuticals Inc. (NASDAQ: ELOX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $13.20 (+0.61% 1D, market cap $53.3M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ELOX ranks #483 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ELOX carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, INKT (MiNK Therapeutics Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $55.5M) and KLRS (Kalaris Therapeutics Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $50.7M). Among the 5-stock peer group, ELOX leads on earnings multiple (N/A) while ELOX leads on capital efficiency (-35.0% ROIC).
Per ELOX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001035354), Eloxx Pharmaceuticals Inc. generated $0 in revenue (-100.0% YoY), -$6.0M in net income, and -$6.3M in free cash flow against $5.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
FRED Regime × Technicals: 33% of 52W Range • RSI-14 at 45.4 (NEUTRAL RANGE)
20D Institutional Volume Accumulation (±12.5% realized swing band)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While ELOX currently carries a cautious 42/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($15.34) and Max Pain ($13.86) forces dealer call-delta covering toward $24.57.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Eloxx Pharmaceuticals Inc. (ELOX) advanced +0.61% to $13.20, trading at 33% of its 52-week range ($8.2 – $23.4). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), a clinical-stage biopharmaceutical company developing exaluren for the treatment of rare kidney diseases, today announced that the U.S. Food and Drug Administration (FDA) has c
Guggenheim analyst Vamil Divan maintains Eloxx Pharma (NASDAQ:ELOX) with a Buy and lowers the price target from $43 to $40.
Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), a clinical-stage biopharmaceutical company developing exaluren for the treatment of rare kidney diseases, today announced the finalized design of its EXPRESS Phase 2 global stu
Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), a clinical-stage biopharmaceutical company developing exaluren for the treatment of rare kidney diseases, today announced the finalized design of its EXPRESS Phase 2 global
Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), a clinical-stage biopharmaceutical company developing exaluren for the treatment of rare kidney diseases, today announced the appointment of Geno Germano to its Board of Direct
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ELOX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ELOX. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Eloxx Pharmaceuticals Inc. (ELOX) ranks #483 by composite RQD confidence (42/100, grade D-) and #741 by equity capitalization ($53.3M). Within this direct 5-issuer industry benchmark cohort, ELOX leads on earnings valuation at N/A trailing P/E, while ELOX leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. INKT currently holds the highest overall quantitative score in the immediate peer group at 43/100 (D-) compared with ELOX at 42/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ELOX
ACTIVE
Eloxx Pharmaceuticals Inc. | D- | 42/100 | — | — | -35.0% | +0.61% | $53.3M | Benchmark Subject |
| INKT MiNK Therapeutics Inc. | D- | 43/100 | — | — | -35.0% | +0.69% | $55.5M | /inkt-vs-elox → |
| KLRS Kalaris Therapeutics Inc. | E | 31/100 | — | — | -35.0% | +5.97% | $50.7M | /klrs-vs-elox → |
| CRBU Caribou Biosciences Inc. | E | 33/100 | — | — | -35.0% | -9.07% | $47.7M | /crbu-vs-elox → |
| TIL Instil Bio Inc. | D- | 39/100 | — | — | -35.0% | +0.52% | $46.3M | /til-vs-elox → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Eloxx Pharmaceuticals Inc. (ELOX) reported GAAP revenue of $0 (-100.0% vs. FY2024 revenue of $6.4M ) , GAAP net income of -$6.0M, operating cash flow of -$6.3M, and free cash flow of -$6.3M (-34.2% YoY). On the balance sheet, ELOX closed FY2025 with $5.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$6.0M | -$6.3M | -$6.3M | $5.3M | $0 |
| FY2024 (FY) | 2024-12-31 | $6.4M | -$3.1M | -$4.7M | -$4.7M | $3.0M | $0 |
| FY2023 (FY) | 2023-12-31 | $0 | -$17.1M | -$14.3M | -$14.3M | — | — |
As of 2026-11-02, Eloxx Pharmaceuticals Inc. (NASDAQ: ELOX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $13.20 (+0.61% 1D, market cap $53.3M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ELOX ranks #483 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ELOX carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, INKT (MiNK Therapeutics Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $55.5M) and KLRS (Kalaris Therapeutics Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $50.7M). Among the 5-stock peer group, ELOX leads on earnings multiple (N/A) while ELOX leads on capital efficiency (-35.0% ROIC).
Per ELOX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001035354), Eloxx Pharmaceuticals Inc. generated $0 in revenue (-100.0% YoY), -$6.0M in net income, and -$6.3M in free cash flow against $5.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
ELOX last traded at $13.20 (+0.61% on volume of 46,895 shares), positioning the stock -13.95% below its 50-day simple moving average ($15.34) and -10.14% below its 200-day simple moving average ($14.69). Across its 52-week range of $8.20 to $23.40, ELOX sits at the 32.9% percentile with a 14-day RSI of 45.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($11.55 to $14.85).
Why ELOX Stock advanced +0.61% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).